2026年A股首个交易日，市场一片热闹景象。 一方面，上证指数再度站上4000点，日线迎来罕见的12连阳。另一方面，权重股搭台，个股普涨，热点全面开花。 权重股方面，保险板块大涨；此外，贵州茅台（600519）、宁德时代（300750）、中芯国际等龙头股均上涨。板块方面，脑机接口、医药、半导体、消费 电子等板块大涨。 截至上午收盘，上证指数上涨1.07%，报4011.45点；深证成指上涨1.87%，创业板指上涨2.15%。 | 新华保险 融 601336 | 74.95 | 7.53% | 1563 Z | | --- | --- | --- | --- | | 中国太保 | 44.49 | 6.16% | 3045亿 | | 融 601601 | | | | | 行业龙头3 | | | | | 中国平安 ■ 601318 | 72.20 | 5.56% | 7697亿 | | 行业龙头2 | | | | | 中国人寿 融 601628 | 47.85 | 5.16% | 9964 Z | | 行业龙头1 | | | | | 中国人保 融 601319 | 9.38 | 4.80% | 3330亿 | 202 ...

Investment Rating - The industry investment rating is "Positive" (maintained) [1] Core Views - The report highlights that various segments within the pharmaceutical industry have seen multiple stocks with over 100% gains in 2025, particularly in the chemical preparation sector, which has outperformed due to the rise in valuations of innovative drugs and strong clinical data from pipelines [4][13] - The report anticipates continued opportunities in the innovative drug sector, driven by the global competitiveness of Chinese pharmaceutical companies and the recognition of their R&D capabilities by multinational corporations [5][14] - Emerging industries such as AI, brain-computer interfaces, and biomanufacturing are expected to gradually transform various segments of the pharmaceutical field, with ongoing efforts to identify investment opportunities within these areas [5][14] Summary by Sections 1. Performance of Pharmaceutical Segments - In 2025, the chemical preparation sector showed the best performance, with top stocks like Shuyou Shen, Guangsheng Tang, and Anglikang achieving over 100% gains due to favorable clinical data and valuation increases [4][13] - The bioproducts sector, including companies like Sanofi and Rongchang Biopharma, also saw significant gains driven by quality pipelines and business development opportunities abroad [4][13] - The pharmaceutical R&D outsourcing sector experienced a "Davis Double" effect, with companies like WuXi AppTec and Haoyuan Pharmaceutical reporting exceptional performance due to increased demand and exceeding expectations [4][13] 2. Market Trends and Weekly Performance - In the fifth week of December 2025, the pharmaceutical sector declined by 2.06%, underperforming the CSI 300 index by 1.47 percentage points, ranking 28th among 31 sub-industries [6][18] - The hospital sector had the smallest decline at 0.85%, while the offline pharmacy sector faced the largest drop at 4.11% [6][22] 3. Recommendations and Focus Areas - The report continues to recommend investment in the innovative drug sector and its supply chain, particularly in CXO and R&D services, as well as in emerging industries like AI and biomanufacturing [5][7][14] - Monthly and weekly stock recommendations include WuXi AppTec, Sanofi, and Haoyuan Pharmaceutical, among others, indicating a focus on companies with strong growth potential [7][15]

Core Viewpoint - The article discusses the performance of stocks categorized as "猛兽股" (beast stocks), focusing on those with a price increase of over 4 times within a year, and highlights the emergence of two distinct trading patterns: the traditional trend model and the volume accumulation model [1][2]. Group 1: Stock Selection Criteria - The selection formula for identifying beast stocks is based on a specific calculation involving the highest high and lowest low over a defined period [1]. - A total of 99 stocks were identified in the market, with 40 stocks filtered through an earnings pre-selection pool, although the specific list is not provided [2]. Group 2: Market Trends and Patterns - The current bull market has seen a significant increase in the volume accumulation model, with a ratio of approximately 6:4 compared to the traditional model [2]. - The volume accumulation model results in steeper price increase slopes and shorter time frames for achieving similar gains, with some stocks completing significant price movements in just days or weeks [2]. - The rise of quantitative trading is closely linked to the volume accumulation model, which emphasizes high-frequency trading and rapid turnover, previously dominated by speculative funds [2]. Group 3: Differences Between Trading Models - The traditional trend model is closely tied to earnings growth, while the volume accumulation model shows little correlation with earnings performance [2][5]. - Stocks selected under the traditional model are fundamentally different from those in the volume accumulation model, reflecting divergent views on the importance of fundamentals versus short-term market sentiment [4][5]. Group 4: Commonalities and Market Implications - Both trading models exhibit a common principle of minimal drawdowns during trends, with only a small fraction of the selected stocks experiencing significant pullbacks [5]. - The average drawdown for potential bull stocks in 2025 is lower than in previous years, theoretically making it easier to hold positions [5]. - The emergence of the volume accumulation model presents both challenges and opportunities for investors, suggesting a need for diversification in investment strategies [5].

Core Viewpoint - The innovative pharmaceutical sector is expected to perform well in 2026, driven by strong business development (BD) activities and supportive industrial policies, despite recent market adjustments [1][4]. Group 1: Market Performance - The Hong Kong innovative drug index has seen a year-to-date increase of nearly 70%, with individual stocks like Shuyou Shen and Sanofi Biopharma doubling in price [1][2]. - In the A-share market, stocks such as Shuyou Shen and Sanofi Biopharma have also experienced significant gains, with Shuyou Shen's price soaring nearly 7 times at one point [2]. - The Hong Kong stock market has welcomed over 20 pharmaceutical companies this year, with notable first-day performances, including a nearly 300% increase for Yinnuo Pharmaceutical [2][3]. Group 2: Business Development (BD) Trends - The number of BD projects in the Chinese innovative drug sector reached 166 by December 5, 2025, marking an increase of 54 projects from the previous year [4]. - The total amount of BD transactions has reached $141.97 billion, a growth of over 136.8% compared to 2024, with upfront payments totaling $6.3 billion, up by over 199% [4][5]. - Major deals include a $13 billion transaction between Qiguang Dekang and Biohaven, and a collaboration between Sanofi Biopharma and Pfizer worth up to $48 billion [4][5]. Group 3: Future Outlook - Analysts predict that the innovative drug sector will continue to thrive in 2026, with a shift in focus from quantity to value in BD transactions [7]. - The industry is expected to see a selection of high-quality companies emerge as leaders, supported by a stable policy environment and improved market confidence [7][8]. - The innovative drug sector is anticipated to remain a core focus within the pharmaceutical industry, with significant benefits expected for related sectors such as CXO [7][8].

舒泰神公告，香塘集团及一致行动人2024年12月03日至2025年12月26日通过深交所集中竞价及大宗交易 累计减持1554.92万股，减持比例3.2545%，持股比例由8.26%降至4.9999%，不再为持股5%以上股东； 本次权益变动未导致公司控股股东、实际控制人变化。 ...

舒泰神（北京）生物制药股份有限公司 简式权益变动报告书 上市公司名称：舒泰神（北京）生物制药股份有限公司 信息披露义务人：香塘集团有限公司 住 所：太仓市娄东街道上海东路168号3幢2003室 通讯地址：太仓市娄东街道上海东路168号3幢2003室 通讯地址：太仓市娄东街道上海东路168号3幢 股份变动性质：股份减少，持股比例下降至5%以下 签署日期：2025年12月29日 1 一致行动人1：苏州香塘同轩科技有限公司 住 所：太仓市沙溪镇昭溪路88号1幢 通讯地址：太仓市沙溪镇昭溪路88号1幢 一致行动人2：顾振其 通讯地址：太仓市娄东街道上海东路168号3幢 一致行动人3：顾晓磊 上市地点：深圳证券交易所 股票简称：舒泰神 股票代码：300204 信息披露义务人声明 一、本报告书系依据《中华人民共和国公司法》《中华人民共和国证券法》 《上市公司收购管理办法》《公开发行证券的公司信息披露内容与格式准则第15 号——权益变动报告书》及其他相关法律、法规和规范性文件编写。 二、信息披露义务人签署本报告书已获得必要的授权和批准，其履行亦不违 反信息披露义务人章程或内部规则中的任何条款，或与之相冲突。 三、根据《中华 ...

证券代码：300204 证券简称：舒泰神 公告编号：2025-085 舒泰神（北京）生物制药股份有限公司 关于持股 5%以上股东及其一致行动人减持至 5%以下暨权益变动的提示性公告 持股 5%以上股东香塘集团有限公司及其一致行动人保证信息披露的内容真 实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 特别提示： 2024年12月03日至2025年12月26日，信息披露义务人通过深圳证券交易所集 中竞价交易系统及大宗交易系统对外累计减持本公司无限售条件流通股股份 1,554.9200万股，减持比例为3.2545%。 1、本次权益变动不会导致公司控股股东、实际控制人发生变化； 2、本次权益变动后，香塘集团有限公司（以下简称"香塘集团"）及其一致 行动人不再是持有公司 5%以上股份的股东。 舒泰神（北京）生物制药股份有限公司（以下简称"公司"或"舒泰神"）于 2025 年 12 月 29 日收到持股 5%以上股东香塘集团及其一致行动人出具的《简式权益 变动报告书》、《关于持股比例降至 5%以下暨权益变动的告知函》， ...

Group 1 - The core viewpoint of the news is that Shutaishen's stock has shown significant volatility, with a year-to-date increase of 275.17% and recent fluctuations in trading volume and price [1][2] - As of December 25, Shutaishen's stock price was 27.80 yuan per share, with a total market capitalization of 13.282 billion yuan [1] - The company has experienced a net outflow of main funds amounting to 23.4642 million yuan, with large orders showing a buy-sell imbalance [1] Group 2 - Shutaishen's main business involves the research, production, and sales of biological products and some chemical drugs, with the primary revenue sources being the injection of mouse nerve growth factor (59.17%) and compound polyethylene glycol electrolyte powder (33.19%) [1] - As of September 30, the company reported a revenue of 181 million yuan for the first nine months of 2025, a year-on-year decrease of 30.82%, and a net profit attributable to shareholders of -30.6895 million yuan, a decrease of 227.71% [2] - The company has not distributed any dividends in the last three years, with a total payout of 771 million yuan since its A-share listing [3]

Core Viewpoint - The stock of Shuyou Shen experienced a decline of 2.01% on December 23, with a current price of 26.88 yuan per share and a total market capitalization of 12.843 billion yuan. The company has seen significant fluctuations in its stock price throughout the year, with a year-to-date increase of 262.75% but a recent decline over the past 20 and 60 days [1]. Financial Performance - For the period from January to September 2025, Shuyou Shen reported a revenue of 181 million yuan, representing a year-on-year decrease of 30.82%. The net profit attributable to the parent company was -30.6895 million yuan, a decline of 227.71% compared to the previous year [2]. Shareholder Information - As of September 30, 2025, the number of shareholders for Shuyou Shen was 46,500, an increase of 46.97% from the previous period. The average number of circulating shares per shareholder was 9,745, which decreased by 31.98% [2]. Dividend Distribution - Since its A-share listing, Shuyou Shen has distributed a total of 771 million yuan in dividends. However, there have been no dividend distributions in the last three years [3]. Institutional Holdings - Among the top ten circulating shareholders as of September 30, 2025, Xingshan He Run Mixed A ranked as the third-largest shareholder with 12.2691 million shares, a decrease of 3.4519 million shares from the previous period. Xingshan He Yi Mixed A ranked fifth with 9.3396 million shares, an increase of 3.3875 million shares [3].

今天看到一个很有意思的新闻，说，阿里的千问，发布了"2025十大AI提示词"，也就是统计了一下，大家最爱找AI问什么问题，虽然我现在对千 问的能力有比较大的质疑，其C端基数也还完全不够打，但看看也无妨。 " 本次入选的十大高频提示词分别为： 股票、八字、情感咨询、朋友圈文案、景点推荐、双色球号码、失眠、解答这道题、离婚财产分割、人 生的意义 。 " 从前三大提示词可以看出，发财、升官、（）老婆/公，确实一直是中国人 最硬核的人生目标，也是最困扰大家的。 不过这个榜单有一个地方有点看不懂，双色球每次开奖都是独立的随机事件，理论上历史的结果无法影响下一期，所以，大家问双色球号码是为了啥？ 而"解答这道题"，确实是很实用的场景，现在把题目用AI拍照提问，可以给出非常完整的解题过程，解决了大量三年级及以上家长，无力教子女写作业的 问题。 另外，个人感觉，未来C端用户足够大的大模型公司，都能自己搞个量化公司炒股，因为投资的本质是"人性"，是"相信相信的力量"，是"寻找共 识"，大模型有了足够多的客户基数后，可以相对准确地刻画出人性和一致预期，这些用户自己输入的语料，可以最终凝练为非常好的量化因 子，比现在量化从全市场的 ...